chemotherapy Archives

Oncotarget News

Figure 1: (A) Sliced fresh tumor samples were cultured in 96-well plates and viability was measured with PrestoBlue daily for 5 days. X-axis is days, and Y-axis is proportion of viability. (B) Sliced fresh tumor samples were embedded with paraffin, and tissue sections were stained with hematoxylin and eosin (H&E), Masson trichrome, αSMA, CD34 and Ki-67 antibodies.

Real-Time Live Tissue Sensitivity Assay for Pancreatic Adenocarcinoma

September 19, 2023

This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma.”BUFFALO, NY- September 19, 2023 – A new research paper was... read more

Figure 1: Response to docetaxel in second or third line treatment for non-small cell lung cancer after a treatment with chemo-immunotherapy.

Oncotarget

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

June 7, 2023

large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.”BUFFALO, NY- June 7, 2023 –... read more

Figure 6: Synergistic/antagonistic combinations.

Oncotarget

Oncotarget | Selective Protection of Normal Cells From Chemotherapy, While Killing Drug-Resistant Cancer Cells

March 13, 2023

Selective protection of normal cells may transform therapy of cancer.” BUFFALO, NY- March 13, 2023 – A new review paper was published in Oncotarget's Volume 14 on March 11, 2023,... read more

Figure 2: Histopathological evaluation of oral mucositis on days 4, 8, 12 and 15. (truncated)

Oncotarget

Oncotarget | The Chromatographic Constitution of Andiroba Oil and its Healing Effects…

January 24, 2023

The andiroba extract in wounds provides acceleration in healing process, with increase of contraction rate and local re-epithelialization, resulting in the complete closure of wounds [52].” BUFFALO, NY- January... read more

Figure 1: Demographic factors, comorbidities and therapy regime of the melanoma patients in percentage, age in years.

Oncotarget

Oncotarget | Impact of Covid-19 on Management of Patients With Metastatic Melanoma

January 11, 2023

In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” BUFFALO, NY- January 11, 2023 – A new research... read more

“Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention.”

Oncotarget

Behind the Study: APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

December 13, 2022

Dr. Kerri Winters-Stone and Dr. Jacob Raber from Oregon Health and Science University, describe a research paper they co-authored that was published by Oncotarget in Volume 13, entitled, “Association of... read more

Oncotarget

Oncotarget | Mutation Analysis Performed on Tumor Biopsies From Patients With Newly-Diagnosed Germinal Center Aggressive B Cell Lymphomas

November 17, 2022

Our analysis demonstrates that the presence of CREBBP mutations in tumor biopsies from patients with newly-diagnosed GCB DLBCL/HGBL is associated with poorer DFS [disease free survival] following treatment with... read more

Oncotarget

Oncotarget | Predictive Molecular Biomarkers for Determining Neoadjuvant Chemosensitivity in Muscle Invasive Bladder Cancer

November 8, 2022

To our knowledge, our study is the first to use combined differential mRNA and miRNA expression in MIBC to identify a NAC response signature.”BUFFALO, NY- November 8, 2022 – A... read more

Oncotarget

Oncotarget | Effectiveness of Radiotherapy for Local Control in T3N0 Rectal Cancer Managed With Total Mesorectal Excision: A Meta-analysis

October 13, 2022

To the best of our knowledge, this is the first study to date to perform a systematic review or meta-analysis regarding the benefit of radiotherapy specific to the T3N0 rectal... read more

Oncotarget

Oncotarget | Targeting Krebs-cycle-deficient RCC with Poly ADP-ribose Polymerase Inhibitors, Low-dose Alkylating Chemotherapy

September 20, 2022

In this study, we sought to examine the activity of combined TMZ and PARPi in Krebs-cycle-deficient renal cancer models.”BUFFALO, NY- September 20, 2022 – A new research paper was published... read more